Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs ...

Retrieved on: 2025-03-20 17:51:01

Tags for this article:

Click the tags to see associated articles and topics

Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs .... View article details on hiswai:

Excerpt

Phase II include, BioNTech SE. Key Players. BioNTech SE. Y-mAbs Therapeutics. Seagen Inc. Key Products. BNT111. GD2-SADA. SEA-CD40. For more ...

Article found on: finance.yahoo.com